FYERS
Home
/
Stocks
/
Profit Loss
/
Syncom Formulations (India) Profit & Loss

Syncom Formulations (India) Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Dec 2013Mar 2013Dec 2012Mar 2012
₹126 Cr₹135 Cr₹115 Cr₹122 Cr₹117 Cr₹149 Cr₹128 Cr₹102 Cr₹87 Cr₹75 Cr₹65 Cr₹64 Cr₹60 Cr₹61 Cr₹57 Cr₹54 Cr₹51 Cr₹58 Cr₹57 Cr₹53 Cr₹41 Cr₹35 Cr₹34 Cr₹27 Cr
₹8 Cr₹15 Cr₹6 Cr₹5 Cr₹6 Cr₹7 Cr₹4 Cr₹4 Cr₹1 Cr₹3 Cr₹5 Cr₹4 Cr₹2 Cr₹7 Cr₹2 Cr₹3 Cr₹3 Cr₹6 Cr₹2 Cr₹3 Cr₹25 L₹49 L₹40 L₹53 L
₹133 Cr₹150 Cr₹121 Cr₹127 Cr₹123 Cr₹156 Cr₹132 Cr₹106 Cr₹89 Cr₹78 Cr₹70 Cr₹68 Cr₹62 Cr₹68 Cr₹59 Cr₹57 Cr₹54 Cr₹64 Cr₹59 Cr₹56 Cr₹41 Cr₹35 Cr₹35 Cr₹27 Cr
₹101 Cr₹116 Cr₹95 Cr₹105 Cr₹102 Cr₹132 Cr₹114 Cr₹91 Cr₹78 Cr₹66 Cr₹59 Cr₹58 Cr₹54 Cr₹56 Cr₹53 Cr₹51 Cr₹49 Cr₹57 Cr₹53 Cr₹48 Cr₹37 Cr₹33 Cr₹31 Cr₹27 Cr
₹34 Cr₹37 Cr₹27 Cr₹24 Cr₹22 Cr₹25 Cr₹19 Cr₹16 Cr₹12 Cr₹13 Cr₹12 Cr₹10 Cr₹8 Cr₹13 Cr₹8 Cr₹7 Cr₹6 Cr₹8 Cr₹7 Cr₹8 Cr₹5 Cr₹3 Cr₹4 Cr₹1 Cr
₹25 L₹38 L₹26 L₹27 L₹25 L₹12 L₹20 L₹16 L₹39 L₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹72 L₹62 L₹50 L₹1 Cr₹15 L₹12 L₹2 L₹9 L₹11 L₹15 L
₹32 Cr₹34 Cr₹25 Cr₹22 Cr₹20 Cr₹23 Cr₹17 Cr₹15 Cr₹10 Cr₹10 Cr₹9 Cr₹8 Cr₹6 Cr₹10 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹6 Cr₹7 Cr₹4 Cr₹2 Cr₹3 Cr₹20 L
₹25 Cr₹25 Cr₹19 Cr₹17 Cr₹16 Cr₹18 Cr₹13 Cr₹11 Cr₹8 Cr₹7 Cr₹7 Cr₹7 Cr₹4 Cr₹8 Cr₹4 Cr₹4 Cr₹4 Cr₹5 Cr₹4 Cr₹6 Cr₹3 Cr₹1 Cr₹2 Cr-₹85 L

Share Price Live Stats

Open (₹)19.69
Volume (₹)33.31 L
High (₹)19.85
Upper Circuit23.35
Low (₹)18.60
Lower Circuit15.57
Prev Close19.46
52W High (₹)22.59
Price18.82
52W Low (₹)10.21

Share Market Cap & Key Ratios Overview

M.Cap (₹)1833.94 Cr
Div. Yield (%)0.00
PE Ratio21.44
Debt to Equity0.01
Price to Book4.52
Book Value3.64
EPS (TTM)0.91
Face Value1.00
ROE (%)15.69

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
MANKINDNSE
SYNCOMFNSE
LTP
1W Low
1W High
Market cap (₹)
1842.7-18.3 (-0.98%)
1828
1856.80
4,41,957Cr
9239.5-199 (-2.11%)
9213
9415
2,47,576Cr
4885-45 (-0.91%)
4875
4988
1,89,233Cr
1112.5-5.3 (-0.47%)
1104.60
1135.50
1,11,671Cr
1354.2-19.1 (-1.39%)
1347.70
1373
1,10,273Cr
1947.8+2.8 (0.14%)
1918.10
1981.80
1,06,460Cr
1152.4+9.4 (0.82%)
1130
1182
96,906Cr
1672.4+4 (0.24%)
1655.50
1688
96,402Cr
2073.4-4.4 (-0.21%)
2058
2108.50
95,843Cr
2281.3+42.9 (1.92%)
2222
2291.50
94,050Cr
18.82-0.44 (-2.28%)
18.51
20.10
1,834Cr

Key Highlights of Syncom Formulations (India) Ltd’s P&L

In 2025-03-31, Syncom Formulations (India) Ltd reported total revenue of ₹482.45Cr, compared with ₹276.91Cr in 2024-03-31, reflecting Syncom Formulations (India) Ltd turnover.

Depreciation was ₹5.19Cr and finance costs were ₹86.49Lakh in 2025-03-31

Profit Before Tax (PBT) has been ₹65.51Cr in 2025-03-31 as compared to ₹33.95Cr in 2024-03-31.

Net Profit (PAT) was ₹49.43Cr in 2025-03-31 compared with ₹25.31Cr in 2024-03-31.

Earnings per share (EPS) were ₹0.53 in 2025-03-31, compared with ₹0.27 in 2024-03-31.